Frezza, Anna Maria <br/><br/>
Is [F-18]-fluorodeoxy-D-glucose positron emission tomography of value in the management of patients with craniofacial bone sarcomas undergoing neo-adjuvant treatment?  [electronic resource] 

 -  BMC cancer  Jan 2014 
 - 23 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1471-2407 
<br/><br/><label>Standard No.: </label>10.1186/1471-2407-14-23  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Bone Neoplasms--diagnostic imaging<br/>Chemotherapy, Adjuvant<br/>Disease Progression<br/>Disease-Free Survival<br/>Facial Bones--diagnostic imaging<br/>Fluorodeoxyglucose F18<br/>Humans<br/>Kaplan-Meier Estimate<br/>Magnetic Resonance Imaging<br/>Male<br/>Middle Aged<br/>Multimodal Imaging<br/>Necrosis<br/>Neoadjuvant Therapy<br/>Neoplasm Recurrence, Local<br/>Osteosarcoma--diagnostic imaging<br/>Positron-Emission Tomography<br/>Predictive Value of Tests<br/>Radiopharmaceuticals<br/>Retrospective Studies<br/>Skull--diagnostic imaging<br/>Time Factors<br/>Tomography, X-Ray Computed<br/>Treatment Outcome<br/>Young Adult